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In this issue of Blood, Volz et al. establish a potential anti-tumor strategy by exploiting 
the selective requirement for platelets to maintain vascular integrity within the tumor 
microenvironment.1 Their work demonstrates, for the first time, that functional inhibition of 
platelet-specific surface receptor glycoprotein (GP) VI, using F(ab’)2 fragments to avoid platelet 
clearance, increases intratumoral hemorrhage and concomitant tumor cell apoptosis, as well as 
enhanced accumulation of chemotherapeutic drugs. These effects work additively to inhibit 
tumor growth, achieving results similar to those achieved by platelet depletion.2,3 
Among platelet receptors, GPVI possesses the rare property of being nonessential for 
hemostasis but its loss or blockade prevents arterial thrombosis, making GPVI an attractive 
target. Indeed, Revacept, a soluble dimeric GPVI fusion protein, is currently in phase II trials as 
an anti-thrombotic therapy.4 Platelets are small circulating anucleate cell fragments that are 
essential for hemostasis, but platelets are increasingly recognized as mediators of a broad 
range of hematologic functions. Platelets have been shown to safeguard the integrity of 
developing and dysfunctional vessels under inflammatory conditions. GPVI was recently 
established as an essential mediator of vascular integrity in inflammatory settings.5 The tumor 
microenvironment is one such setting. The study by Volz et al. is the first to investigate this 
function of GPVI in solid tumors. Using both orthotopic and heterotopic models of tumor 
implantation in mice, they demonstrate increased intratumoral hemorrhage with either GPVI 
depletion in the host, or acute GPVI inhibition using an F(ab’)2 fragment of JAQ1 - an antibody 
that blocks the major collagen binding site on murine GPVI . The results achieved are similar to 
those obtained with acute platelet depletion.2,6 The treatments directed against GPV1 also 
increased the accumulation of chemotherapeutic drugs in the tumors. With anti-cancer drugs 
given every 4 days, the authors observed additive effects of GPVI inhibition or platelet depletion 
on tumor growth suppression. This provides proof of concept for combined GPVI targeting with 
chemotherapeutic drugs as a potentially effective anti-tumor approach targeting specific platelet 
functions but with minimal bleeding complications. 
Unlike most current anti-platelet antibodies, the JAQ1 F(ab’)2 fragment does not lead to 
platelet clearance. Thus, the ability of JAQ1 F(ab’)2 to induce intratumoral hemorrhage can be 
attributed to molecular blockade of GPVI on circulating platelets, although contributions of 
plasma GPVI shed from platelets cannot be ruled out. This in itself is a striking result, as it 
indicates that GPVI exposure is the principal mediator of platelet-dependent vascular integrity. 
Of particular note is that mechanisms of GPVI-dependent vascular integrity in inflammation 
appear to vary depending upon the extent of vascular damage and the underlying context.7 In 
the case of small breaks in the endothelial barrier exposing sub-endothelial collagen and 
laminin, single platelets can plug the leak via GPVI engagement in many inflammatory settings.  
This may be the case in dysfunctional tumor vasculature.8 Indeed, Volz et al. were able to 
reproduce the hemorrhage and tumor growth inhibition of JAQ1 F(ab’)2 using soluble dimeric 
GPVI-Fc fusion protein, which competes for platelet-collagen binding, providing further support 
for this mechanism in the solid tumor models. However, GPVI inhibition caused massive 
intratumoral hemorrhage beyond what might be anticipated by single platelet-sized gaps in 
endothelium. Earlier studies demonstrated that infiltrating leukocytes are the major drivers of 
platelet-dependent intratumoral hemorrhage.9 One possible explanation for the increased 
intratumoral hemorrhage in GPVI-blocked mice could involve multiple steps. GPVI is required 
initially to establish single platelet plugs via anchorage and spreading on sub-endothelial matrix.  
In the absence or blockade of GPVI, inflammatory cells – principally neutrophils – infiltrate and 
induce further vascular damage thereby increasing the extent of hemorrhage, as observed by 
Volz et al.1 Neutrophil recruitment to the tumor microenvironment was not altered by GPVI 
inhibition, supporting a role for GPVI in either preventing or possibly repairing vascular damage 
induced from neutrophils. However, neutrophil depletion did not fully prevent hemorrhage by 
GPVI blockade, indicating contributions from other factors. Tumor-associated macrophages, 
other inflammatory cells, as well as plasma GPVI, may also play important roles. Moreover, 
platelet-derived permeability factors such as serotonin, vascular endothelial growth factor and 
angiopoietin-1 have not yet been investigated in this context.2 Dynamic studies of platelet and 
leukocyte interactions with the vessel wall in tumor models, coupled with analysis of soluble 
factors, will be essential to elucidating the cellular and molecular basis for intratumoral 
hemorrhage induced by GPVI blockade. 
 Platelets influence solid cancer progression through many mechanisms, and new roles 
for platelets are continually emerging. A striking outcome of the study from Volz et al. is the 
provocative notion that GPVI inhibition could have anti-cancer clinical utility by taking advantage 
of several of these mechanisms. First, GPVI inhibition caused tumor cell apoptosis and reduced 
growth of solid tumors by selectively driving intratumoral hemorrhage. Second, increased 
vascular permeability selectively in tumors potentiated intratumoral accumulation of commonly 
used cancer chemotherapeutics – both paclitaxel and liposomal doxorubicin. Third, GPVI 
depletion has been shown to limit metastatic dissemination in some ectopic tumor models in 
mice, although metastasis was not tested in this study.10 While it is established that GPVI 
modulation blocks thrombosis but is permissive for hemostasis, GPVI blockade also appears to 
have no effect on integrity of intact vessels. Together, these properties of GPVI inhibition 
support an attractive multi-faceted approach to multi-stage cancer treatment, with potentially 
limited side effects compared to current anti-platelet therapeutic approaches. However, 
inflammation may present a substantial obstacle, as GPVI inhibition may also drive hemorrhagic 
responses at inflammatory sites other than the targeted tumor tissue. Hence, though GPVI 
blockade in combination with chemotherapeutic regimens may help deliver the triple-play to 
knock out malignancy, underlying inflammation may also be targeted with potentially dangerous 
results. It will be critical to determine whether effects of GPVI targeting in solid tumors reflect a 
common mechanism of increased hemorrhage at inflammatory sites, or if those effects are 
unique to the tumor microenvironment. 
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